

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein do not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein will be offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein is being or will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock Code: 2359)

**ADJUSTMENT TO THE CONVERSION PRICE OF US\$300 MILLION
ZERO COUPON CONVERTIBLE BONDS DUE 2024**
(Stock Code: 6015)

References are made to the (i) announcements of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” together with its subsidiaries, the “**Group**”) dated September 3, 2019, September 4, 2019, September 5, 2019 and September 17, 2019 in relation to the issue of US\$300 million zero coupon convertible bonds due 2024 (the “**Bonds**”); and (ii) the circular of the Company dated March 31, 2020 (the “**Circular**”) and the poll results announcement of the Company dated May 15, 2020 (the “**Poll Results Announcement**”) in relation to, among other things, the Profit Distribution and Capitalization of Reserve. Unless otherwise stated, the terms used in this announcement shall have the same meanings as defined in the Circular.

As disclosed in the Poll Results Announcement, the Company will distribute cash dividends for the year ended December 31, 2019 and conduct Capitalization of Reserve. An aggregate amount of RMB556,429,640.95 (inclusive of tax) (representing a dividend of RMB3.37 (inclusive of tax) per ten (10) Shares based on the total issued Shares as at the date of this announcement) and a total of 660,450,612 Shares comprising 68,205,424 New Capitalization H Shares and 592,245,188 New Capitalization A Shares based on the Company's total share capital of 1,651,126,531 Shares will be issued on the basis of four (4) Capitalization Shares for every existing ten (10) Shares by way of capitalization of reserve.

Pursuant to the terms and conditions of the Bonds, the price at which H Shares will be issued upon conversion ("**Conversion Price**") is subject to adjustment for, among other things, capital distributions and capitalization of profits or reserves made by the Company. The Company therefore announces that the Conversion Price of the Bonds will be adjusted from HK\$111.80 per H Share, being the initial Conversion Price to HK\$79.85 per H Share (the "**Adjusted Conversion Price**") as a result of the approval of the payment of Profit Distribution and the Capitalization of Reserve by the Shareholders at the 2019 AGM with effective from June 4, 2020, being the day immediately after the record date for determining H Shareholders' entitlement to the Capitalization of Reserve and Profit Distribution. Save as disclosed above, all other terms of the Bonds remain unchanged.

Assuming full conversion of the Bonds at the Adjusted Conversion Price, the H Shares that may be convertible and issuable under the Bonds will increase from approximately 21,048,032 H Shares to approximately 29,469,881 H Shares, representing 17.28% of the total issued H share capital of the Company as at the date of this announcement and approximately 10.99% of the enlarged total issued H share capital of the Company resulting from the full conversion of the Bonds and the completion of the Capitalization of Reserve. The additional 8,421,849 H Shares issuable in the event of a full conversion of the Bonds after the Adjusted Conversion Price becoming effective will be allotted and issued by the Company pursuant to the general mandate sought and granted at the 2019 AGM held on May 15, 2020.

This announcement also serves as a notification to the holders of the Bonds in respect of the adjustment to the Conversion Price in accordance with the trust deed constituting the Bonds entered into between the Company and The Hongkong and Shanghai Banking Corporation Limited on September 17, 2019.

Any holder of the Bonds who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, June 3, 2020

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*